相似文献
1
SEOM guidelines for the management of Malignant Melanoma 2015.
Clin Transl Oncol. 2015 Dec;17(12):1030-5. doi: 10.1007/s12094-015-1450-4. Epub 2015 Dec 15.
2
SEOM clinical guideline for the management of malignant melanoma (2017).
Clin Transl Oncol. 2018 Jan;20(1):69-74. doi: 10.1007/s12094-017-1768-1. Epub 2017 Nov 7.
3
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.
Eur J Cancer. 2020 Feb;126:159-177. doi: 10.1016/j.ejca.2019.11.015. Epub 2019 Dec 19.
5
SEOM clinical guideline for the management of cutaneous melanoma (2020).
Clin Transl Oncol. 2021 May;23(5):948-960. doi: 10.1007/s12094-020-02539-9. Epub 2021 Mar 2.
6
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.
Eur J Cancer. 2016 Aug;63:201-17. doi: 10.1016/j.ejca.2016.05.005. Epub 2016 Jun 29.
7
The adjuvant treatment revolution for high-risk melanoma patients.
Semin Cancer Biol. 2019 Dec;59:283-289. doi: 10.1016/j.semcancer.2019.08.024. Epub 2019 Aug 21.
8
SEOM-GEM clinical guidelines for cutaneous melanoma (2023).
Clin Transl Oncol. 2024 Nov;26(11):2841-2855. doi: 10.1007/s12094-024-03497-2. Epub 2024 May 15.
9
Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Recent Results Cancer Res. 2000;157:178-89. doi: 10.1007/978-3-642-57151-0_15.
10
Management of V600E and V600K BRAF-Mutant Melanoma.
Curr Treat Options Oncol. 2019 Nov 18;20(11):81. doi: 10.1007/s11864-019-0680-z.
引用本文的文献
1
Comparison of large language models in management advice for melanoma: Google's AI BARD, BingAI and ChatGPT.
Skin Health Dis. 2023 Nov 28;4(1):e313. doi: 10.1002/ski2.313. eCollection 2024 Feb.
2
Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool.
Clin Transl Oncol. 2024 Jan;26(1):85-97. doi: 10.1007/s12094-023-03219-0. Epub 2023 Jun 27.
3
Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma.
Mol Clin Oncol. 2016 Oct;5(4):458-462. doi: 10.3892/mco.2016.978. Epub 2016 Aug 4.
4
SEOM Guidelines 2015: a new era in the collaboration with the Spanish Cancer Research Cooperative Groups.
Clin Transl Oncol. 2015 Dec;17(12):937-8. doi: 10.1007/s12094-015-1478-5. Epub 2015 Dec 17.
本文引用的文献
1
Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial.
Lancet Oncol. 2016 Feb;17(2):184-192. doi: 10.1016/S1470-2045(15)00482-9. Epub 2016 Jan 12.
2
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med. 2015 Sep 24;373(13):1270-1. doi: 10.1056/NEJMc1509660.
3
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.
4
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
J Clin Oncol. 2015 Jun 10;33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9.
5
Nivolumab in previously untreated melanoma without BRAF mutation.
N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
6
Improved overall survival in melanoma with combined dabrafenib and trametinib.
N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
7
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.
8
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
N Engl J Med. 2014 Nov 13;371(20):1877-88. doi: 10.1056/NEJMoa1406037. Epub 2014 Sep 29.
9
Interferon alpha for the adjuvant treatment of cutaneous melanoma.
Cochrane Database Syst Rev. 2013 Jun 18;2013(6):CD008955. doi: 10.1002/14651858.CD008955.pub2.
10
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Lancet Oncol. 2012 Nov;13(11):1087-95. doi: 10.1016/S1470-2045(12)70431-X. Epub 2012 Oct 8.
Zotero 插件